中国经济网北京9月4日讯 （记者 康博） 截至8月29日，在有可比业绩的976只（各份额分开计算， 下同）普通股票型基金中，今年前8月业绩实现上涨的基金数量为969只，占比高达99%，仅有7只普通 股基业绩出现下跌。 华安医药生物股票发起式A/C承接此前的上涨态势，以107.64%和107.03%的涨幅位居榜首。也是唯 一一只涨幅翻倍的普通股票型基金。从其二季报看，该基金重仓信达生物、石药集团、康方生物、三生 制药、泽璟制药、百济神州、云顶新耀、信立泰、迈威生物、海南海药。从二级市场走势看，前四只个 股与迈威生物的年内涨幅均翻倍，其中的三生制药更是暴涨超过4倍。 资料显示，华安医药生物股票由桑翔宇管理，其曾任鹏华基金管理有限公司助理研究员，2018年9 月加入华安基金，此前历任投资研究部研究员、基金经理助理。 涨幅在90%以上的普通股基被嘉实、富国与鹏华基金包揽，分别为嘉实互融精选股票A、嘉实互融 精选股票C、富国医药创新股票A、富国医药创新股票C、鹏华医药科技股票A、鹏华医药科技股票C， 涨幅在91.34%至98.55%不等。 而且这三只基金的基金经理全部为资深人士，比如嘉实互融精选的基金经理郝淼，其原为中 ...

Group 1 - In the first half of 2025, 822 out of 993 comparable ordinary stock funds achieved positive performance, representing 83% of the total [1] - The top three performing funds saw gains exceeding 60%, with 华安医药生物股票发起式A at 66.44%, 华安医药生物股票发起式C at 66.07%, and 嘉实互融精选股票A at 60.26% [1][2] - 华安医药生物股票发起式 has a cumulative return of over 68% since its inception, heavily investing in pharmaceutical companies such as 三生制药 and 信达生物 [1] Group 2 - 嘉实互融精选股票 also focuses on pharmaceutical stocks, with top holdings including 康方生物 and 百济神州, and has shown significant growth exceeding 55% in the first half of 2025 [2] - Several other pharmaceutical-themed funds, including 平安医药精选股票 and 富国医药创新股票, also reported gains over 55% [2] - Conversely, 11 ordinary stock funds experienced declines exceeding 10%, with 长信消费精选量化股票C and A dropping 12.38% and 12.20% respectively, primarily due to their focus on the consumer sector [2][3] Group 3 - The 长信消费精选量化股票 fund, which is heavily invested in the liquor sector, has seen a cumulative decline of 50% since its establishment [3] - 北信瑞丰优选成长 fund, managed by a relatively inexperienced manager, has not included any pharmaceutical stocks in its top holdings since 2022, focusing instead on liquor stocks [3] - Other funds with significant declines include 民生加银优选股票, which fell by 10.64%, and 广发高端制造股票C and A, which dropped by 10.57% and 10.39% respectively [4]

Core Viewpoint - The A-share market has shown strong performance in the first half of 2025, with the Shanghai Composite Index stabilizing above 3400 points and reaching a new high for the year [1] Group 1: Investment Strategies for the Second Half - Investors often mistakenly believe that strong-performing funds from the first half will continue to perform well in the second half, which is a significant misconception in fund investment [3] - The best-performing funds in the first half of 2023 were those focused on the Hong Kong innovative pharmaceutical sector, with several ETFs and equity funds achieving over 50% gains [4] - Historical data indicates that funds that performed well in the first half often see a decline in performance by the end of the year, as seen with AI and gaming-focused funds in 2023 [4][5] Group 2: Focus Areas for Investment - The technology growth sector is expected to become a key market focus again in the second half, driven by strong performances in the U.S. stock market, particularly in AI-related companies [6] - The robotics sector remains a promising area for investment, with several funds achieving over 40% gains despite previous adjustments due to valuation concerns [7] - Dividend funds are gaining popularity due to their stable cash flow and bond-like characteristics, with many achieving positive returns in 2023 [10] Group 3: REITs Market Expansion - The REITs market has been expanding, with a total of 73 products now available, focusing on emerging sectors like new infrastructure and smart cities [12] - REITs have shown strong performance in 2023, with specific products like the Jia Shi Wu Mei Consumption REIT and Hua Xia Da Yue Cheng Commercial REIT achieving over 50% and 49.58% gains, respectively [12]